mazadapharmaguide.com Open in urlscan Pro
68.171.213.17  Public Scan

Form analysis
4 forms found in the DOM

POST View

<form method="POST" action="View">
  <div class="form-check-inline">
    <label class="form-check-label" for="radio1">
      <input name="optSearch" onclick="setType('P')" type="radio" class="form-check-input" id="radio1" value="Products" checked="">By Products </label>
  </div>
  <div class="form-check-inline">
    <label class="form-check-label" for="radio2">
      <input name="optSearch" onclick="setType('C')" type="radio" class="form-check-input" id="radio2" value="Companies">By Company </label>
  </div>
  <!--<div class="input-group-prepend">
								<span class="input-group-text">$</span>
							</div>-->
  <input name="txtSearch" type="text" class="form-control" id="txtSearchP" placeholder="Enter Products" style="width: 100%;margin-bottom: 10px;">
  <div class="input-group-append">
    <!-- <div data-toggle="modal" data-target="#myModal" id="btnGo" onclick="getCompProducts()" class=" form-control btn btn-primary"> Go</div> -->
    <input name="submit" value="Go" type="submit" class=" form-control btn btn-primary">
  </div>
</form>

POST ../Advertisers/index.php

<form method="POST" action="../Advertisers/index.php">
  <input type="text" class="form-control" style="width: 100%;margin-bottom: 10px;" id="OwnerInputEmail" name="OwnerInputEmail" placeholder="username">
  <input type="password" class="form-control" style="width: 100%;margin-bottom: 10px;" id="OwnerInputPassword" name="OwnerInputPassword" placeholder="password">
  <button class="form-control btn btn-warning" name="LoginBtn" type="submit">Login</button><br>
  <!--<button class="form-control btn btn-info" name="RegAdvtBtn" type="submit">New Advertiser</button>-->
</form>

POST DigitalEditions

<form id="DigitalE" action="DigitalEditions" method="POST">
  <input id="txtEdition525" name="txtEdition" type="hidden" value="The Mazada Pharma Guide">
</form>

POST DigitalEditions

<form id="DigitalE" action="DigitalEditions" method="POST">
  <input id="txtEdition" name="txtEdition" type="hidden" value="The Mazada Pharma Guide">
</form>

Text Content

X
X
Mazda Publications invites articles on Latest Products, Technology, Policy
Trends without being too Company/ Brand or Product specific.

Kindly email Your Contributions to:
Mr Anurag More
Sub Editor
Mazda Publications
Email: mazdapharmaguide@gmail.com
Www.chemicalsourcingguide.com


Printing of the Article will be at Sole Discretion of the Publisher and Reason
for acceptance or rejection of same is not answerable.
Mazada Pharma Guide

 * Home
   
 * About Us
   Company Profile Mission and Values Business Achievements
 * Pricing
   Print Tariff Print Packages Web Tariff Web Packages
 * Our Product
   
   MAGAZINES
   
   The Mazada Pharma Guide Chemical Sourcing Guide
   
   --------------------------------------------------------------------------------
   
   DIRECTORIES
   
   All India Formulators Directory All India API, Bulk Drugs Directory
   
   --------------------------------------------------------------------------------
   
   SUPPLEMENTS
   
   CPHI India Special Supplement - 2020
 * Contact
 * Subscription
 * Advertise with us
 * News

Find Suppliers
By Products
By Company

P
Advertisers'
Lead Manager
Login

Digital Editions
The Mazada Pharma Guide


PREMIUM ADVERTISERS

Profile
Visit Website Contact

Profile
Visit Website Contact

Profile
Visit Website Contact


ADVERTISERS

11







PPP



PR NEWSWIRE






News provided by PR Newswire
 * Seizing a Threefold Victory! PM-International Malaysia Wins Three Awards at
   the Asia Pacific Enterprise Awards 2024 Malaysia
   SINGAPORE, 2 hours ago
   SINGAPORE, July 4, 2024 /PRNewswire/ -- The Asia Pacific Enterprise Awards
   (APEA) 2024 Malaysia culminated in a spectacular celebration of innovation,
   perseverance, and inclusive growth on 7th June…
 * If You Purchased, Paid, or Provided Reimbursement for Some or All of the
   Price of Branded Lipitor® or its Generic Equivalent, Atorvastatin Calcium,
   You Could Get Money From a Settlement
   TRENTON, N.J., 3 hours ago
   TRENTON, N.J., July 3, 2024 /PRNewswire/ -- YOUR LEGAL RIGHTS MAY BE AFFECTED
   There is a proposed settlement in a class-action lawsuit filed against Pfizer
   Inc., Pfizer Ireland Pharmaceuticals,…
 * LOTTE BIOLOGICS Holds Groundbreaking for Songdo Bio Campus
   SEOUL, South Korea, 3 hours ago
   Plans to Join the Ranks of the TOP 10 Global CDMOs, Heralding a New Era in
   the Global CDMO LandscapeSEOUL, South Korea, July 3, 2024 /PRNewswire/ -- In
   a landmark event signaling its ambitious foray…
 * Docquity accelerates growth for pediatric multivitamin distributor Green
   Nature Farm in Indonesia
   JAKARTA, Indonesia, 5 hours ago
   GNF leverages Docquity's Awareness to Advocacy (A2A) Program and local
   partnerships to build HCP relationships and expand distribution across
   Indonesia over seven yearsGNF hits 20% of its overall…
 * Ascentage Pharma Received US$100 Million Option Payment from Takeda
   ROCKVILLE, Md. and SUZHOU, China, Thu, Jul 4 2024 02:07
   ROCKVILLE, Md. and SUZHOU, China, July 3, 2024 /PRNewswire/ -- Ascentage
   Pharma (6855.HK), a global biopharmaceutical company engaged in discovering,
   developing and commercializing both…
 * Whitman-Walker Institute Condemns Nationwide Injunction Blocking Federal
   Nondiscrimination Protections for Transgender People Following a 'Shameful'
   Decision in Tennessee Case
   WASHINGTON, Thu, Jul 4 2024 01:52
   WASHINGTON, July 3, 2024 /PRNewswire/ -- Whitman-Walker Institute condemns
   the politically motivated ruling from a federal district court judge that
   blocks vital nondiscrimination protections for…
 * Feminine Hygiene Wash Market size is set to grow by USD 124.8 million from
   2024-2028, Advertising and promotion of feminine hygiene wash products to
   boost the market growth, Technavio
   NEW YORK, Wed, Jul 3 2024 23:50
   NEW YORK, July 3, 2024 /PRNewswire/ -- The global feminine hygiene wash
   market size is estimated to grow by USD 124.8 million from 2024-2028,
   according to Technavio. The market is estimated to grow…
 * Cinnamon Market size is set to grow by USD 412.9 million from 2024-2028,
   Rising awareness about health benefits of cinnamon to boost the market
   growth, Technavio
   NEW YORK, Wed, Jul 3 2024 23:45
   NEW YORK, July 3, 2024 /PRNewswire/ -- The global cinnamon market size is
   estimated to grow by USD 412.9 million from 2024-2028, according to
   Technavio. The market is estimated to grow at a CAGR of…
 * Mixed Martial Arts Equipment Market size is set to grow by USD 252.6 million
   from 2024-2028, Growing popularity of women's MMA to boost the market growth,
   Technavio
   NEW YORK, Wed, Jul 3 2024 23:35
   NEW YORK, July 3, 2024 /PRNewswire/ -- The global mixed martial arts
   equipment market size is estimated to grow by USD 252.6 million from
   2024-2028, according to Technavio. The market is estimated…
 * BCG Unresponsive NMIBC Market to Register Sustainable Growth During the Study
   Period (2020-2034) | DelveInsight
   LAS VEGAS, Wed, Jul 3 2024 23:31
   The BCG unresponsive NMIBC market is anticipated to witness a substantial
   positive shift owing to better uptake of existing drugs, the expected market
   launch of photodynamic therapy and non-viral…
 * The Inner Circle acknowledges, Sharon E. Oster, MD as a Pinnacle Lifetime
   Member
   BOISE, Idaho, Wed, Jul 3 2024 23:15
   BOISE, Idaho, July 3, 2024 /PRNewswire/ -- Prominently featured in The Inner
   Circle, Sharon E. Oster, MD, is acknowledged as a Pinnacle Life Member for
   her contributions to the fields of Internal…
 * Aronia Berries Market size is set to grow by USD 501.5 million from
   2024-2028, Health benefits of aronia berries boost the market, Technavio
   NEW YORK, Wed, Jul 3 2024 23:10
   NEW YORK, July 3, 2024 /PRNewswire/ -- The global aronia berries market size
   is estimated to grow by USD 501.5 million from 2024-2028, according to
   Technavio. The market is estimated to grow at a…
 * Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar
   Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
   VICTORIA, BC, Wed, Jul 3 2024 23:00
   Osteoarthritis ("OA") is the leading cause of disability in older adults.The
   U.S. Centers for Disease Control and Prevention estimates that knee OA
   affects more than 30 million people in the U.S.…

1 2 3  >   >> 



NEWS

Flight Passengers from Thailand and Singapore to be universally screened in
addition to those from China and Hong Kong
Union Minister of Health & Family Welfare Dr. Harsh Vardhan chaired a review
meeting on preparedness for management of Novel Coronavirus with senior officers
of the Ministry, here today.
Cabinet Secretary also held a high-level review meeting on the preparedness for
Novel Coronavirus with Secretaries of Health, Civil Aviation, Textiles,
Pharmaceutical, DHR, and Dte. General of Foreign Trade (DGFT). Cabinet Secretary
has held five review meetings so far.
As of today, 52,332 passengers from 326 flights have been screened. A total of
97 symptomatic travelers picked up by the IDSP have been referred to the
isolation facilities. 98 samples have been tested of which 97 have been found to
be negative. The earlier positive case found in Kerala is being monitored and is
stable.
In addition, Secretary (HFW) had a video conference to review the process of
screening passengers from different countries. Apart from passengers coming from
China and Hong Kong, passengers coming on flights from Singapore and Thailand
shall also be universally screened at the airports, henceforth. Shri Pradeep
Singh Kharola, Secretary (Civil Aviation), Health Secretaries from all States
for the 21 airports, Airport Public Health Officers from these airports, along
with representatives from the Bureau of Immigration, Customs Department were
present.
The 324 incoming Indian citizens from Wuhan, China have reached today. Of these,
104 are housed at ITBP Chawla Camp and 220 are in Manesar. They are being
effectively monitored.
New Beginning for Indian Pharmaceuticals and Standards
The Indian Pharmacopoeia (IP) has been recognised formally by the National
Department of Regulation of Medicines and Health Products of the Ministry of
Public Health of Islamic Republic of Afghanistan. It will also be used based on
the requirement as reputable pharmacopoeia in the laboratory of medicines and
health products quality. With this, a new beginning has been made and
Afghanistan has become the first country to recognize IP pursuant to the efforts
of Department of Commerce and Ministry of Health and Family Welfare.
IP is an officially recognized book of standards as per the Drugs and Cosmetics
Act, 1940 and Rules 1945 thereunder. The IP specifies the standards of drugs
manufactured and marketed in India in terms of their identity, purity and
strength.
The quality, efficacy and safety of the medicines are important from healthcare
perspective. In order to ensure the quality of medicinal products, the legal and
scientific standards are provided by Indian Pharmacopoeia Commission (IPC) in
the form of Indian Pharmacopoeia (IP). As per, the Second Schedule of the Drugs
and Cosmetics Act, IP is designated as the official book of standards for drugs
imported and/or manufactured for sale, stock or exhibition for sale or
distribution in India.
The IP Commission’s mission is to promote public and animal health in India by
bringing out authoritative and officially accepted standards for quality of
drugs including active pharmaceutical ingredients, excipients and dosage forms,
used by health professionals, patients and consumers. This is achieved by
developing the standards for medicines and supporting their implementation. In
addition, IPC also develops IP Reference Substances (IPRS) that act as
fingerprint for identification of an article under test and its purity as
prescribed in the IP monographs. Standards prescribed in the IP are
authoritative in nature and are enforced by the regulatory authorities for
quality control of medicines in India.
Setting up of National Investment & Manufacturing Zones
Government notified the National Manufacturing Policy(NMP) in 2011. The Policy
is based on the principle of industrial growth in partnership with the States.
National Investment & Manufacturing Zones (NIMZs) are one of the important
instruments of the policy. Government has already granted final approval to the
NIMZ in Sangareddy district, Telangana. Further, the proposal for granting final
approval of establishment of Hyderabad Pharma City NIMZ in Rangareddy district,
Telangana has been considered and recommended by the High Level Committee (HLC).
A letter of Chief Minister of Telangana was received in which CM has requested
to release an amount of Rs. 500 Crores for development of external and internal
infrastructure under Phase-1 of Zaheerabad NIMZ in Sangareddy district of
Telangana. In this regard, Department for Promotion of Industry and Internal
Trade(DPIIT) had already conveyed to the State Government of Telangana that
DPIIT’s financial commitment is limited to extending assistance of Rs. 3 crores
for funding the cost of master planning. For development of infrastructure in
the NIMZ, the role of DPIIT is limited to coordination and no finances from
DPIIT are committed for this purpose. The project proposals need to be prepared
by the State Government and processed for approval as per norms and procedures
applicable to Central Sector/ Centrally Sponsored/State Sector schemes/projects.
DPIIT will forward such requisitions to the concerned Ministries and coordinate
between State Government and line Ministries.
DPIIT has already released Rs. 3 Crores to the SPV of NIMZ for funding the cost
of master planning of NIMZ in Sangareddy district of Telangana. The Department
had also forwarded the proposals, submitted by TSIIC, of External infrastructure
linkages, i.e. Road linkages and Rail linkages, for phase-1 of the said NIMZ to
the Ministry of Road Transport and Highways and Ministry of Railways
respectively. The comments of Ministry of Railways have already been conveyed to
Government of Telangana. Further, no proposal for internal infrastructure in the
NIMZ has been received from the State Government.
The progress of NIMZ in Sangareddy district of Telangana was further reviewed on
14th November, 2019, in the 6th meeting of High Level Committee.
This information was given by the Minister of Commerce and Industry, Piyush
Goyal, in a written reply in the Lok Sabha today.
Cabinet approves extension/renewal of the extant Pharmaceuticals Purchase Policy
(PPP) with the same terms and conditions.
The Union Cabinet chaired by Prime Minister Shri Narendra Modi today approved
extension/renewal of Pharmaceuticals Purchase Policy (PPP) for pharmaceutical
Central Public Sector Undertakings (CPSUs) till their closure/strategic
disinvestment.
Major Impact
Extension/renewal of the policy would help the pharma CPSUs in optimum
utlilization of their existing facilities, enable them to generate revenues to
pay salaries to their employees, help them in keeping the costly, sophisticated
machinery in running condition resulting in higher return at the time of
disposal in case of CPSUs under closure and better valuation in case of CPSUs
under disinvestment.
Background
Pharmaceuticals Purchase Policy (PPP) was approved by the Cabinet on 30.10.2013
for a period of five years in respect of 103 medicines manufactured by pharma
CPSUs and their subsidiaries. The policy is applicable to purchases by Central/
State Government departments and their Public Sector Undertakings etc. The
pricing of the products is done by National Pharmaceutical Pricing Authority
(NPPA). The procuring entity can purchase from Pharma CPSUs and their
subsidiaries subject to their meeting Good Manufacturing Practices (GMP) norms
as per Schedule ‘M’ of the Drugs & Cosmetic Rules. The term of the policy
expired on 09.12.2018.
Meanwhile, Cabinet decided on 28.12.2016 to close Indian Drugs and
Pharmaceutical Limited (IDPL) & Rajasthan Drugs and Pharmaceuticals Limited
(RDPL) and strategically sell Hindustan Antibiotics Limited (HAL) & Bengal
Chemicals and Pharmaceutical Limited (BCPL), after meeting their liabilities
from proceeds of sale of their surplus land to government agencies.
Subsequently, Cabinet has modified its decision on 17.07.2019 permitting to sell
surplus land as per revised Department of Public Enterprises guidelines dated
14.06.2018. Separately, Cabinet Committee on Economic Affairs (CCEA) decided on
01.11.2017 for disinvestment of 100% GOI equity in the fifth pharma CPSU, namely
Karnataka Antibiotics & Pharmaceuticals Limited (KAPL).
It has been proposed to extend the policy till final closure/sale of pharma
CPSUs.
Digital Editions 2024
The Mazada Pharma Guide

Media Partner
ICC Sustainability Conclave 2024
4th Computer Software Assurance 2024
Drug Safety Symposium 2024 India Chapter





--------------------------------------------------------------------------------

Pharma India Expo

--------------------------------------------------------------------------------



--------------------------------------------------------------------------------

Asia Labex

--------------------------------------------------------------------------------

Ankeleshwar Industrial Expo

--------------------------------------------------------------------------------

India Lab Expo & Analytica Anacon India

--------------------------------------------------------------------------------

Asia Labex

--------------------------------------------------------------------------------

IPHEX

--------------------------------------------------------------------------------

Pharmac South

--------------------------------------------------------------------------------

Pharma Pro&Pack Expo

--------------------------------------------------------------------------------

India Lab Expo & Analytica Anacon India

--------------------------------------------------------------------------------

CPHI India

--------------------------------------------------------------------------------

Industrial Expo

--------------------------------------------------------------------------------

Pharma Live Expo

--------------------------------------------------------------------------------

HPCI

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------


ADDRESS

1 A , Sharma Compound , Old Nagardas Road
Opp Abhudaya Bank , Andheri East, Mumbai
Maharashtra 400069


EMAIL

mazdapharmaguide@gmail.com




CONTACT

8652813388

Designed by Humans Information Technology Solutions
Copyright: Mazda Publications
Digital Editions ×

Leads ×